Allarity Therapeutics (ALLR) Income from Non-Controlling Interests (2022 - 2023)
Allarity Therapeutics' (ALLR) quarterly Income from Non-Controlling Interests came in at $180000.0 in Q2 2023, up 205.08% YoY from $59000.0 in Q2 2022, and up 248.76% on a QoQ basis from -$121000.0 in Q1 2023.
Allarity Therapeutics (ALLR) Income from Non-Controlling Interests (2022 - 2023) Analysis & Trends
Allarity Therapeutics (ALLR) has 2 years of Income from Non-Controlling Interests data on file, last reported at $180000.0 in Q2 2023.
- Quarterly Income from Non-Controlling Interests rose 205.08% year-over-year to $180000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $524000.0 (changed N/A YoY) and the FY2020 annual result came in at -$15000.0, changed N/A from the prior year.
- Income from Non-Controlling Interests rose to $180000.0 in Q2 2023, from -$121000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $1.1 million in Q1 2022 to a low of -$121000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Allarity Therapeutics | 22.75 Mn | 22.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 180,000.00 |
| Mar 31, 2023 | -121,000.00 |
| Sep 30, 2022 | 406,000.00 |
| Jun 30, 2022 | 59,000.00 |
| Mar 31, 2022 | 1.07 Mn |